61571-96-8Relevant academic research and scientific papers
An efficient, continuous flow technique for the chemoselective synthesis of thioacetals
Wiles, Charlotte,Watts, Paul,Haswell, Stephen J.
, p. 7362 - 7365 (2008/03/13)
By optimizing a reagent's residence time within a packed-bed reactor, it is possible to overcome selectivity issues frequently encountered in stirred reaction vessels. This important feature is demonstrated for the chemoselective protection of 4-acetylben
Δ9-tetrahydrocannabinol immunochemical studies: Haptens, monoclonal antibodies, and a convenient synthesis of radiolabeled Δ9-tetrahydrocannabinol
Qi, Longwu,Yamamoto, Noboru,Meijler, Michael M.,Altobell III, Laurence J.,Koob, George F.,Wirsching, Peter,Janda, Kim D.
, p. 7389 - 7399 (2007/10/03)
Immunopharmacotherapy as an approach to combat drugs of abuse has become an active area of investigation. Marijuana is the most commonly used illicit drug in the U.S. The main active chemical in marijuana is Δ9- tetrahydrocannabinol (Δ9-THC); hence, monoclonal antibodies with high affinity and specificity for Δ9-tetrahydrocannabinol could be valuable immunopharmacotherapeutic intervention and diagnostic tools. We have synthesized immunoconjugates that induce an effective immune response to Δ9-THC and describe a convenient synthesis of radiolabeled Δ9-THC. We demonstrate the value and use of this probe to select anti-Δ9-THC antibodies that bind Δ9-THC with good affinity. The synthetic route to radiolabeled Δ9-THC has enabled the correct assessment of the affinity of these antibodies to their ligand and may facilitate future binding studies between Δ9- THC and its analogues and the cannabinoid receptors.
Pharmacophoric requirements for the cannabinoid side chain. Probing the cannabinoid receptor subsite at C1′
Papahatjis, Demetris P.,Nikas, Spyros P.,Kourouli, Therapia,Chari, Ravi,Xu, Wei,Pertwee, Roger G.,Makriyannis, Alexandros
, p. 3221 - 3229 (2007/10/03)
Earlier work from our laboratories has provided evidence for the existence of a subsite within the CB1 and CB2 cannabinoid receptor binding domain corresponding to substituents at the benzylic side chain position of classical cannabinoids. The existence a
